LAVAL,
QC, May 17, 2023 /PRNewswire/ -- Acasti Pharma
Inc. ("Acasti" or the "Company") (Nasdaq: ACST), a late-stage,
biopharma company advancing GTX-104, its novel formulation of
nimodipine that addresses the high unmet medical needs for a rare
disease, aneurysmal subarachnoid hemorrhage (aSAH), announced today
that Prashant Kohli, CEO, will be
participating in a Company Webcast and Panel Presentation at the
Lytham Partners Spring 2023 Investor Conference on Thursday, May 18, 2023. Management will also be
conducting one-on-one meetings with investors.
Company Webcast
The Company's webcast presentation will be available for viewing
at 9:00 am ET on Thursday, May 18,
2023, on the Company's website at
https://www.acasti.com/en/investors or
https://wsw.com/webcast/lytham8/acst/2033325. The webcast will also
be archived and available for replay.
Panel Presentation
Additionally, Mr. Kohli will be participating in a panel titled,
"Phase 3 Drugs to Watch." This panel, also to be conducted
virtually, will be held on Thursday, May 18,
2023, at 2:00 pm ET. To access
the panel, please visit:
https://wsw.com/webcast/lytham8/panel3/2272725.
1x1 Meetings
Management will be participating in virtual one-on-one meetings
throughout the event. To arrange a meeting with management, please
contact Lytham Partners at 1x1@lythampartners.com or register
at https://www.lythampartners.com/spring2023invreg/.
About Acasti
Acasti is a late-stage biopharma company with drug candidates
addressing rare and orphan diseases. Acasti's novel drug delivery
technologies have the potential to improve the performance of
currently marketed drugs by achieving faster onset of action,
enhanced efficacy, reduced side effects, and more convenient drug
delivery. Acasti's lead clinical assets have each been granted
Orphan Drug Designation by the FDA, which provides seven years of
marketing exclusivity post-launch in the
United States, and additional intellectual property
protection with over 40 granted and pending patents. Acasti's lead
clinical asset, GTX-104, is an intravenous infusion targeting
aneurysmal Subarachnoid Hemorrhage (aSAH), a rare and
life-threatening medical emergency in which bleeding occurs over
the surface of the brain in the subarachnoid space between the
brain and skull. For more information, please visit:
https://www.acasti.com.
Forward-Looking Statements
Statements in this press release that are not statements of
historical or current fact constitute "forward-looking statements"
within the meaning of the U.S. Private Securities Litigation Reform
Act of 1995, as amended, Section 27A of the Securities Act of 1933,
as amended, and Section 21E of the Securities Exchange Act of 1934,
as amended, and "forward-looking information" within the meaning of
Canadian securities laws (collectively, "forward-looking
statements"). Such forward looking statements involve known and
unknown risks, uncertainties, and other factors that could cause
the actual results of Acasti to be materially different from
historical results or from any future results expressed or implied
by such forward-looking statements. In addition to statements which
explicitly describe such risks and uncertainties, readers are urged
to consider statements containing the terms "believes," "belief,"
"expects," "intends," "anticipates," "estimates", "potential,"
"should," "may," "will," "plans," "continue", "targeted" or other
similar expressions to be uncertain and forward-looking. Readers
are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release.
The forward-looking statements in this press release are based upon
Acasti's current expectations and involve assumptions that may
never materialize or may prove to be incorrect. Actual results and
the timing of events could differ materially from those anticipated
in such forward-looking statements as a result of various risks and
uncertainties. The foregoing list of important factors that could
cause actual events to differ from expectations should not be
construed as exhaustive and should be read in conjunction with
statements that are included herein and elsewhere, including the
risk factors detailed in documents that have been and are filed by
Acasti from time to time with the Securities and Exchange
Commission and Canadian securities regulators. All forward-looking
statements contained in this press release speak only as of the
date on which they were made. Acasti undertakes no obligation to
update such statements to reflect events that occur or
circumstances that exist after the date on which they were made,
except as required by applicable securities laws. The NASDAQ does
not accept responsibility for the adequacy or accuracy of this
release.
Acasti Contact:
Prashant Kohli
Chief Executive Officer
Tel: 450-686-4555
Email:info@acasti.com
www.acasti.com
Investor Relations:
Robert
Blum
Lytham Partners, LLC
602-889-9700
ACST@lythampartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/acasti-to-participate-in-the-lytham-partners-spring-2023-investor-conference-301826730.html
SOURCE Acasti Pharma Inc.